REKLAMA
OKAZJA

SOPHARMA AD: Merger of the subsidiary "Veta pharma" AD into "Sopharma" AD

2024-01-15 16:13
publikacja
2024-01-15 16:13
Spis treści:

1. REPORT

2. INFORMATION ABOUT THE ENTITY

3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY


Spis załączników:
SFA_2024_Veta_Pharma_EN_espi.pdf  (REPORT)

POLISH FINANCIAL SUPERVISION AUTHORITY
UNI - EN REPORT No 1 / 2024
Date of issue: 2024-01-15
Short name of the issuer
SOPHARMA AD
Subject
Merger of the subsidiary "Veta pharma" AD into "Sopharma" AD
Official market - legal basis
art. 56. 1. 2 of Act on Public Offering.
Unofficial market - legal basis
Contents of the report:
“Sopharma” AD (the Company) notifies that the Board of Directors of "Sopharma" AD adopted a decision to initiate a procedure for the merger of the subsidiary "Veta pharma" AD, UIC: 104111084 in "Sopharma" AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on the Public Offering of Securities. At the start of the procedure Sopharma AD owns 99.98% in the capital of the company.
Annexes
File Description
SFA_2024_Veta Pharma_EN_espi.pdfSFA_2024_Veta Pharma_EN_espi.pdf Merger of the subsidiary "Veta pharma" AD into "Sopharma" AD

SOPHARMA AD
(fullname of the issuer)
SOPHARMA AD Farmaceutyczny (far)
(short name of the issuer) (sector according to clasification
of the WSE in Warsow)
1220 Sofia
(post code) (city)
IlienskoShosse 16
(street) (number)
+359 2 813 42 00 +359 2 936 02 86
(phone number) (fax)
(e-mail) (web site)
nd
(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Date Name Position / Function Signature
2024-01-15 Ognian Donev Executive director
Źródło:Komunikaty spółek (ESPI)
Tematy
Najlepsze konta dla spółek - ranking
Najlepsze konta dla spółek - ranking

Komentarze (0)

dodaj komentarz

Powiązane:

Polecane

Najnowsze

Popularne

Ważne linki